UBS Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $24
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $32
J.P. Morgan Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
Jefferies Reaffirms Their Buy Rating on Pfizer (PFE)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE) and Nautilus Biotechnolgy (NAUT)
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Phathom Pharmaceuticals (PHAT) and Exact Sciences (EXAS)
Research Alert: Solid Q1 Eps Beat, While Revenue Slightly Disappoints; 2025 Guidance Maintained
Pfizer's Financial Outlook: Hold Rating Amidst Short-Term Challenges and Long-Term Potential
Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $28
HSBC Maintains Pfizer(PFE.US) With Buy Rating, Cuts Target Price to $27
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Erasca (ERAS)
Analysts Sound Caution on Pfizer Stock (PFE) Ahead of Q1 Earnings
Pfizer's Stock Outlook: Analysts Weigh In on Future Prospects
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Pfizer (PFE) and Madrigal Pharmaceuticals (MDGL)
Cantor Fitzgerald Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $24
TD Cowen Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $28
Pfizer Analyst Ratings
Bernstein Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
BofA Securities Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $26
BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Cuts Target Price to $30